Cover Image
市場調查報告書

CAR-T細胞療法的全球市場和臨床實驗預測

Global CAR T Cell Therapy Market and Clinical Trials Insight 2022

出版商 KuicK Research 商品編碼 490660
出版日期 內容資訊 英文 240 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
CAR-T細胞療法的全球市場和臨床實驗預測 Global CAR T Cell Therapy Market and Clinical Trials Insight 2022
出版日期: 2017年04月21日 內容資訊: 英文 240 Pages
簡介

本報告提供嵌合抗原受體T細胞 (CAR-T細胞) 療法概要和作用機制,目前臨床實驗進展,今後的開發、上市預測,各企業、各症狀、各相位的詳細趨勢,主要的治療方法的概要 (共99種),未來市場方案,主要參與企業簡介的資訊彙整,為您概述為以下內容。

第1章 嵌合抗原受體 (CAR) T細胞療法:下一代的癌症免疫療法

  • 概要
  • CAR-T技術的歷史沿革與發展

第2章 CAR-T細胞的設計的演進

  • CAR-T細胞結構
  • 第1代CAR
  • 第2、第3代的CAR

第3章 CAR設計的原則

  • CAR遺傳基因改變T細胞:標的
  • CAR遺傳基因改變T細胞:信號

第4章 CAR-T細胞療法的藥物輸送、作用機制

  • CAR-T細胞療法的流程
  • 作用機制

第5章 CAR-T細胞療法的改良方法

  • 簡介
  • CAR-T細胞的腫瘤間品質的標靶化
  • 細胞激素網路的標靶化
  • CAR-T細胞的混合策略
  • 免疫查核點的標靶化

第6章 全球癌症治療的CAR-T細胞臨床實驗趨勢

  • 急性淋巴性白血病
  • 多發性骨髓瘤
  • 腦瘤
  • 淋巴瘤
  • 固態腫瘤

第7章 全球CAR-T細胞療法臨床實驗開發平台:各企業、各症狀、各相位

  • 藥物研發
  • 前臨床
  • 臨床實驗
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 登記前

第8章 CAR-T細胞療法的全球市場方案

  • 概要
  • CAR-T細胞療法的價格估計分析

第9章 CAR-T細胞療法的全球市場規模

  • 癌症免疫療法:各技術的市場佔有率
  • CAR-T細胞療法的市場規模 (以金額為準)

第10章 全球CAR-T細胞療法市場動態

  • 良好的市場指標
  • 課題

第11章 全球CAR-T細胞療法市場:未來展望

第12章 競爭環境

目錄

“Global CAR T Cell Therapy Market and Clinical Trials Insight 2022” report highlights the ongoing clinical and non-clinical advancement in the field of Car T Cell Therapy. As per report findings, the promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients. Currently, there are 99 CAR T Cell based therapies in clinical pipeline and most of them belong to Phase-I and Phase-I/II clinical trials.

In recent years, researchers have identified the chimeric antigen receptor as a potential target for molecular genetics to insert a new epitopes on the receptor region which allows a degree of control of the immune system. CAR T cell therapy satisfy the need to explore new and efficacious adoptive T cell therapy. The gene transfer technology could efficiently introduce the genes encoding CARs into the immune effector cells. The transferring of engineered T cells provides the specific antigen binding in a non-major histocompatibility complex.

The promise of CAR modified T cell therapy derives from its combined immunologic benefits and include the specificity of a targeted antibody, the ability to expand the T cell population and the potential for long term persistence to facilitate the ongoing tumor surveillance. The success in early phase trials, assess the feasibility of evaluating the treatment modality across the multiple centers and in larger patients.

The first commercial application of CAR T Cell based therapy for the treatment of Mantle- Non-Hodgkin's lymphoma is expected to be available from 2020. The anti-CD19 CAR T cell therapy axicabtagene ciloleucel (KTE-C19) is developed by KITE Pharma in collaboration with National Cancer Institute. Currently this therapy is in preregistration phase.

In future, the advancement of CAR T Cell therapy will be largely driven by academia and will require the support for the expensive early phase clinical trials which promise to cover the way for a new form of targeted, exportable immunotherapy for cancer patient. The manufacturing of CD19 CAR T cell therapy CTL019 is in a way which will modernize the process of using the therapy globally. The anticipation of regulatory and manufacturing issues before they arise and proactively addressing the concerns helps to accelerate the process of bringing this promising therapeutic approach to more patients in future.

“Global CAR T Cell Therapy Market and Clinical Trials Insight 2022” report highlights:

  • CAR T Cell Therapies Delivery Pipeline and Mechanism of Action
  • Global CAR T Cell Therapy Clinical Trials for Cancer Treatment
  • Global CAR T Cell Therapies Clinical Pipeline by Company, Indication and Phase
  • Global CAR T Cell Therapies Clinical Pipeline: 99 Therapies
  • CAR T Cell Therapies in Highest Phase: Preregistration
  • Majority of CAR T Cell Therapies in Phase-I/II Trials: 16 Therapies
  • Global Market Scenario of CAR T Cell Therapy
  • Global CAR T Cell Therapy Market Future Prospects

Table of Contents

1. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology

  • 1.1. Overview
  • 1.2. History & Development of CAR-T Technology

2. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design

  • 2.1. Structure of CAR T Cell
  • 2.2. 1nd Generation Chimeric Antigen Receptor
  • 2.3. 2nd & 3nd Generation CAR T Cell

3. Principle of Chimeric Antigen Receptor Design

  • 3.1. CAR Modified T Cells: Targeting
  • 3.2. CAR Modified T Cell: Signaling

4. CAR T Cell Therapies Delivery Pipeline & Mechanism of Action

  • 4.1. Process of CAR T Cell Therapy
  • 4.2. Mechanism of Action

5. Approaches to Improve the CAR T Cell Therapy

  • 5.1. Introduction
  • 5.2. Targeting the Tumor Stroma with CAR T Cells
  • 5.3. Targeting the Cytokine Networks
  • 5.4. Combination Strategies for CAR T Cells
  • 5.5. Targeting the Immune Checkpoints

6. Global CAR T Cell Therapy Clinical Trials for Cancer Treatment

  • 6.1. Acute Lymphoblastic Leukemia
  • 6.2. Multiple Myeloma
  • 6.3. Brain Tumors
  • 6.4. Lymphoma
  • 6.5. Solid Tumors

7. Global CAR T Cell Therapies Clinical Pipeline by Company, Indication & Phase

  • 7.1. Research
  • 7.2. Preclinical
  • 7.3. Clinical
  • 7.4. Phase-I
  • 7.5. Phase-I/II
  • 7.6. Phase-II
  • 7.7. Preregistration

8. Global Market Scenario of CAR T Cell Therapy

  • 8.1. Overview
  • 8.2. Estimated Price Analysis of CAR T Cell Therapy

9. Global Market Size of CAR T Cell Therapy

  • 9.1. Market Share of Cancer Immunotherapy by its Technology
  • 9.2. CAR T Cell Therapy Market Value

10. Global CAR T Cell Therapy Market Dynamics

  • 10.1. Favorable Parameters
  • 10.2. Challenges

11. Global CAR T Cell Therapy Market Future Prospects

12. Competitive L&scape

  • 12.1. Autolus
  • 12.2. Bellicum
  • 12.3. Bluebird
  • 12.4. Celgene
  • 12.5. Cellectis
  • 12.6. Celyad
  • 12.7. Eureka Therapeutics
  • 12.8. Fortress Biotech
  • 12.9. Immune Therapeutics
  • 12.10. Juno Therapeutics
  • 12.11. Kite Pharma
  • 12.12. Novartis
  • 12.13. Sorrento therapeutics
  • 12.14. TILT Biotherapeutics
  • 12.15. Ziopharm

List of Figures and Tables:

  • Figure 1-1: Historical Development of CAR T Cell Therapy
  • Figure 2-1: Structure of Chimeric Antigen Receptor
  • Figure 2-2: First Generation Chimeric Antigen Receptor
  • Figure 2-3: Second Generation Chimeric Antigen Receptor
  • Figure 2-4: Third Generation Chimeric Antigen Receptor
  • Figure 3-1: Targeting Mechanism of Chimeric Antigen Receptor T-Cell
  • Figure 3-2: Signalling Mechanism of Chimeric Antigen Receptor T Cell
  • Figure 4-1: Delivery Pipeline of CAR T Cell Therapy Process
  • Figure 4-2: CAR T Cell Therapy Mechanism of Action
  • Figure 5-1: Strategies to Improve CAR T Cell Therapy
  • Figure 6-1: CAR T Cell Therapy in Brain Tumors
  • Figure 6-2: Chimeric Antigen Receptor Therapy in Lymphoma
  • Figure 6-3: Target of Cancer Cell by Chimeric Antigen Receptor
  • Figure 7-1: Global - CAR T Cell Therapy Clinical Pipeline by Phase (Number), 2017-2022
  • Figure 7-2: Global - CAR T Cell Therapy Clinical Pipeline by Phase (%), 2017-2022
  • Figure 8-1: Adoptive T-Cell Therapy - Open Clinical Trials to Investigate the Efficacy & Safety (%), 2015
  • Figure 8-2: Estimated Cost of T Cell Therapy & CAR T Cell Therapy Per Patient (US$)
  • Figure 9-1: Cancer Immunotherapy - Market Share of by Its Technology* (%)
  • Figure 9-2: Global Cancer Immunotherapeutic Market (US$ Billion), 2016-2022
  • Figure 9-3: Global - Predictive Market of CAR T Cell Therapeutics (US$ Million), 2016-2022
  • Figure 10-1: Favorable Market Parameters of CAR T Cell Therapy
  • Figure 10-2: Challenges to Market Growth of CAR T Cell Therapy
  • Figure 11-1: Future Potential Immuno-Oncology
  • Table 3-1: Antigens which are targeted by Chimeric Antigen Receptor
  • Table 12-1: Clinical Pipelines of Products
Back to Top